A detailed history of Handelsbanken Fonder Ab transactions in Dynavax Technologies Corp stock. As of the latest transaction made, Handelsbanken Fonder Ab holds 45,400 shares of DVAX stock, worth $587,476. This represents 0.0% of its overall portfolio holdings.

Number of Shares
45,400
Previous 45,400 -0.0%
Holding current value
$587,476
Previous $510,000 0.78%
% of portfolio
0.0%
Previous 0.0%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 05, 2024

BUY
$10.73 - $12.58 $194,213 - $227,698
18,100 Added 66.3%
45,400 $510,000
Q4 2023

Feb 01, 2024

BUY
$13.09 - $14.98 $11,781 - $13,482
900 Added 3.41%
27,300 $382,000
Q1 2023

Apr 28, 2023

BUY
$9.44 - $11.88 $46,256 - $58,212
4,900 Added 22.79%
26,400 $259,000
Q4 2021

Feb 08, 2022

BUY
$13.17 - $20.94 $283,155 - $450,210
21,500 New
21,500 $303,000

Others Institutions Holding DVAX

About DYNAVAX TECHNOLOGIES CORP


  • Ticker DVAX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 126,474,000
  • Market Cap $1.64B
  • Description
  • Dynavax Technologies Corporation, a biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. It also manufa...
More about DVAX
Track This Portfolio

Track Handelsbanken Fonder Ab Portfolio

Follow Handelsbanken Fonder Ab and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Handelsbanken Fonder Ab, based on Form 13F filings with the SEC.

News

Stay updated on Handelsbanken Fonder Ab with notifications on news.